Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play
Arch Bronconeumol (Engl Ed). 2019 Feb;55(2):102-103.
doi: 10.1016/j.arbres.2018.03.010.
Epub 2018 Jul 27.
[Article in
English,
Spanish]
Affiliations
- 1 Department of Cardiology, Hospital Virgen de la Salud, Toledo, Spain. Electronic address: maria.lasal@gmail.com.
- 2 Department of Cardiology, Hospital Virgen de la Salud, Toledo, Spain.
- 3 Department of Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain.
- 4 Department of Cardiology, Hospital La Mancha Centro, Alcazar de San Juan, Spain.
No abstract available
MeSH terms
-
Acetamides / therapeutic use*
-
Antihypertensive Agents / therapeutic use*
-
Drug Substitution
-
Drug Therapy, Combination
-
Epoprostenol / analogs & derivatives
-
Epoprostenol / therapeutic use
-
Female
-
Humans
-
Infusion Pumps
-
Middle Aged
-
Phenylpropionates / therapeutic use
-
Pulmonary Arterial Hypertension / drug therapy*
-
Pyrazines / therapeutic use*
-
Pyridazines / therapeutic use
-
Sildenafil Citrate / therapeutic use
-
Tadalafil / therapeutic use
-
Vasodilator Agents / therapeutic use
Substances
-
Acetamides
-
Antihypertensive Agents
-
Phenylpropionates
-
Pyrazines
-
Pyridazines
-
Vasodilator Agents
-
selexipag
-
Tadalafil
-
Sildenafil Citrate
-
Epoprostenol
-
ambrisentan
-
treprostinil